BR112017013113A2 - processo para a preparação de um composto de diaril tio-hidantoína - Google Patents

processo para a preparação de um composto de diaril tio-hidantoína

Info

Publication number
BR112017013113A2
BR112017013113A2 BR112017013113A BR112017013113A BR112017013113A2 BR 112017013113 A2 BR112017013113 A2 BR 112017013113A2 BR 112017013113 A BR112017013113 A BR 112017013113A BR 112017013113 A BR112017013113 A BR 112017013113A BR 112017013113 A2 BR112017013113 A2 BR 112017013113A2
Authority
BR
Brazil
Prior art keywords
preparation
compound
diaryl
thiohydantoin compound
diaryl thiohydantoin
Prior art date
Application number
BR112017013113A
Other languages
English (en)
Other versions
BR112017013113B1 (pt
Inventor
Horvath Andras
Ben Haim Cyril
Erwin Edmond Weerts Johan
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of BR112017013113A2 publication Critical patent/BR112017013113A2/pt
Publication of BR112017013113B1 publication Critical patent/BR112017013113B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/14—Phosphorus; Compounds thereof
    • B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
    • B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
    • B01J27/198—Vanadium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/04—Mixing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

a presente invenção se refere aos processos e intermediários para a preparação do composto (x) que está atualmente sendo investigado para o tratamento de câncer de próstata.
BR112017013113-7A 2014-12-19 2015-12-17 Processo para a preparação de um composto de diaril tio-hidantoína BR112017013113B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094436P 2014-12-19 2014-12-19
US62/094,436 2014-12-19
PCT/US2015/066356 WO2016100652A2 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound

Publications (2)

Publication Number Publication Date
BR112017013113A2 true BR112017013113A2 (pt) 2017-12-26
BR112017013113B1 BR112017013113B1 (pt) 2023-11-21

Family

ID=55168400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013113-7A BR112017013113B1 (pt) 2014-12-19 2015-12-17 Processo para a preparação de um composto de diaril tio-hidantoína

Country Status (33)

Country Link
US (1) US9688655B2 (pt)
EP (4) EP3372585B1 (pt)
JP (2) JP6681902B2 (pt)
KR (1) KR102586059B1 (pt)
CN (1) CN107108507A (pt)
AR (1) AR103228A1 (pt)
AU (1) AU2015364537B2 (pt)
BR (1) BR112017013113B1 (pt)
CA (1) CA2970937A1 (pt)
CY (2) CY1121684T1 (pt)
DK (3) DK3372585T3 (pt)
EA (4) EA201892485A1 (pt)
ES (3) ES2919951T3 (pt)
HR (3) HRP20220750T1 (pt)
HU (2) HUE052475T2 (pt)
IL (1) IL252843A0 (pt)
LT (3) LT3372584T (pt)
MA (1) MA41200B1 (pt)
MD (1) MD3233803T2 (pt)
ME (1) ME03420B (pt)
MX (1) MX2017008179A (pt)
NZ (1) NZ732766A (pt)
PH (1) PH12017501152A1 (pt)
PL (3) PL3372584T3 (pt)
PT (3) PT3372584T (pt)
RS (3) RS61060B9 (pt)
SG (4) SG10201912811QA (pt)
SI (3) SI3233803T1 (pt)
TR (1) TR201904739T4 (pt)
TW (4) TWI689494B (pt)
UA (1) UA123201C2 (pt)
WO (1) WO2016100652A2 (pt)
ZA (1) ZA201704877B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100652A2 (en) * 2014-12-19 2016-06-23 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound
HUE042349T2 (hu) 2014-12-19 2019-06-28 Aragon Pharmaceuticals Inc Eljárás diariltiohidantoin vegyület elõállítására
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN107501237B (zh) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 一种Apalutamide的合成方法
CN108383749B (zh) * 2018-01-30 2021-03-09 杭州科巢生物科技有限公司 阿帕鲁胺的合成方法及其中间体
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CN108314646B (zh) * 2018-04-11 2021-03-19 武汉慧敏科技中心 一种高分散双金属纳米材料制备泌尿生殖***用药物中间体的方法
CN109651256A (zh) * 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法
CN110511207A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN110511206A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide
CN113292535B (zh) * 2021-06-18 2022-07-01 南京方生和医药科技有限公司 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法
CN113402466B (zh) * 2021-06-18 2022-08-16 南京方生和医药科技有限公司 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法
CN115850233A (zh) * 2021-09-24 2023-03-28 南京方生和医药科技有限公司 一种阿帕鲁胺的合成方法
CN115536634A (zh) * 2022-10-17 2022-12-30 上海博悦生物科技有限公司 一种阿帕他胺的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP3412290B1 (en) 2006-03-27 2021-03-03 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8461343B2 (en) * 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
BRPI0912802A2 (pt) * 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
EA019970B8 (ru) * 2009-12-11 2014-11-28 Отифони Терапеутикс Лимитед Производные имидазолидиндиона
SI3124481T1 (en) * 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
BR112012021406B1 (pt) * 2010-02-24 2021-08-10 Medivation Prostate Therapeutics Llc Processos para a síntese dos compostos de diariltioidantoína e diarilidantoína
CN103608333B (zh) * 2011-03-10 2016-01-06 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
CN104379160A (zh) * 2012-03-29 2015-02-25 桑加特公司 双阿司匹林交联聚乙二醇化血红蛋白
US9708289B2 (en) * 2013-05-29 2017-07-18 Hinova Pharmaceuticals Inc. Imidazole diketone compound and use thereof
WO2016100652A2 (en) * 2014-12-19 2016-06-23 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound

Also Published As

Publication number Publication date
LT3233803T (lt) 2019-04-10
TW201945343A (zh) 2019-12-01
MA41200A (fr) 2017-10-25
JP2020114842A (ja) 2020-07-30
PL3233803T3 (pl) 2019-07-31
US9688655B2 (en) 2017-06-27
AU2015364537A1 (en) 2017-07-06
HRP20220750T1 (hr) 2022-09-02
EA201791390A1 (ru) 2017-10-31
TW201639825A (zh) 2016-11-16
EP3233803B1 (en) 2019-01-30
US20160176845A1 (en) 2016-06-23
TWI703132B (zh) 2020-09-01
SI3372584T1 (sl) 2021-08-31
WO2016100652A2 (en) 2016-06-23
LT3372585T (lt) 2022-07-11
HRP20201847T2 (hr) 2021-05-28
DK3372585T3 (da) 2022-05-30
MA41200B1 (fr) 2019-05-31
PT3372584T (pt) 2020-11-13
MD3233803T2 (ro) 2019-07-31
ES2718539T3 (es) 2019-07-02
EP3372584B1 (en) 2020-09-23
HUE052475T2 (hu) 2021-05-28
KR20170095976A (ko) 2017-08-23
DK3233803T3 (en) 2019-04-08
JP6903785B2 (ja) 2021-07-14
IL252843A0 (en) 2017-08-31
HRP20190540T1 (hr) 2019-06-14
SI3233803T1 (sl) 2019-05-31
CY1121684T1 (el) 2020-07-31
DK3372584T5 (da) 2021-05-17
RS58454B1 (sr) 2019-04-30
RS61060B9 (sr) 2021-07-30
TW202031639A (zh) 2020-09-01
CY1123611T1 (el) 2022-03-24
RS61060B1 (sr) 2020-12-31
SG10201912802XA (en) 2020-02-27
EA201892487A1 (ru) 2019-07-31
ES2827549T3 (es) 2021-05-21
PH12017501152A1 (en) 2017-11-27
PL3372584T3 (pl) 2021-07-05
HRP20201847T1 (hr) 2021-03-19
AR103228A1 (es) 2017-04-26
LT3372584T (lt) 2020-12-10
SG11201704969QA (en) 2017-07-28
WO2016100652A3 (en) 2016-08-25
EA201892486A1 (ru) 2019-07-31
TWI683810B (zh) 2020-02-01
PT3372585T (pt) 2022-07-08
UA123201C2 (uk) 2021-03-03
AU2015364537B2 (en) 2020-10-08
SG10201912811QA (en) 2020-02-27
DK3372584T3 (da) 2021-01-04
PT3233803T (pt) 2019-05-20
JP6681902B2 (ja) 2020-04-15
CA2970937A1 (en) 2016-06-23
EP3233803A2 (en) 2017-10-25
ES2827549T9 (es) 2021-07-02
PL3372585T3 (pl) 2022-10-10
TWI753336B (zh) 2022-01-21
EP3372584A1 (en) 2018-09-12
TWI689494B (zh) 2020-04-01
ME03420B (me) 2020-01-20
MX2017008179A (es) 2017-09-18
EP3372585B1 (en) 2022-03-30
EP3372584B9 (en) 2021-03-31
BR112017013113B1 (pt) 2023-11-21
SG10201912805SA (en) 2020-02-27
EA201892485A1 (ru) 2019-07-31
EP3372586A1 (en) 2018-09-12
ZA201704877B (en) 2019-02-27
EP3372585A1 (en) 2018-09-12
SI3372585T1 (sl) 2022-08-31
TR201904739T4 (tr) 2019-05-21
ES2919951T3 (es) 2022-07-29
TW201945342A (zh) 2019-12-01
RS63455B1 (sr) 2022-08-31
CN107108507A (zh) 2017-08-29
NZ732766A (en) 2023-07-28
JP2018501237A (ja) 2018-01-18
HUE042409T2 (hu) 2019-06-28
KR102586059B1 (ko) 2023-10-05

Similar Documents

Publication Publication Date Title
BR112017013113A2 (pt) processo para a preparação de um composto de diaril tio-hidantoína
BR112017013093A2 (pt) processos para a preparação de um composto de diariltio-hidantoína
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
BR112018001400A2 (pt) compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes
BR112017023932A2 (pt) processo para a preparação de epóxido de terpinoleno
EP3094752A4 (en) Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
BR112017006349A2 (pt) derivados de ácido borônico
BR112017006368A2 (pt) derivados de ácido borônico
SG10201900564WA (en) Methods for treating cancer
SG11201702566RA (en) Process gas enhancement for beam treatment of a substrate
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
AR098394A1 (es) Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
BR112015024859A2 (pt) processo e intermediários para a preparação de pregabalina
SV2016005302A (es) Tinturas reactivas fluorescentes, proceso para su producción y su uso
BR112016027819A8 (pt) processo de preparação de derivados de tiazole
IN2014MU01192A (pt)
IN2014MU00195A (pt)
BR112016016397A2 (pt) método para preparar 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carbaldeídos e 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carboxilatos.
BR112019015577B8 (pt) Processo de fluxo contínuo para a produção de derivado de ácido borônico
BR112017015298A2 (pt) processo para a decomposição de material de biomassa contendo lignocelulose?
BR112016028698A2 (pt) preparação de piperidina-4-carbotioamida
IN2014MU00194A (pt)
IN2014MU01196A (pt)
BR112015017326A2 (pt) processo para a produção de 2-alquil-3-butin-2-óis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 213/84 , C07D 401/04

Ipc: C07D 213/84 (2006.01), C07D 401/04 (2006.01), A61K

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2015, OBSERVADAS AS CONDICOES LEGAIS